Back to: Psychedelics, Entheogens, and Consciousness Expansion
The Mystical Dimension of Clinical Psychiatry
A Briefing on Unity and Transformation
On the afternoon of Good Friday, 1962, twenty young divinity students filed into a small chapel in the basement of Boston University’s Marsh Chapel, expecting a two and a half hour Good Friday service. Ten of them, at random, had also just swallowed a capsule of psilocybin. The other ten had swallowed niacin, an active placebo that flushes the skin and warms the face but changes nothing in the mind. None of them knew which capsule they had taken. By the time the service ended, several were lying on the floor of a side room, weeping, praying out loud, certain they had touched something that had no edges.
That afternoon has quietly shaped the last sixty years of a question psychiatry did not expect to be asking: what if the thing that heals a person is not only the molecule, but the meaning the molecule opens onto? This briefing walks through where that question came from, philosophically and experimentally, and where it has landed in the psilocybin and MDMA trials running right now, in 2026. It is a companion to Module 1, and it sits underneath everything else in that module. Every trial, every regulatory decision, every voucher and executive order this course has already walked you through is, underneath the paperwork, an argument about whether a particular kind of experience, the mystical one, belongs inside the practice of medicine.
Two Doors Into the Same Room
Long before anyone put a name to “clinical efficacy,” the philosopher William James was already asking what made a religious experience convincing to the person having it. His student, in a manner of speaking, was Walter Terence Stace, a philosopher who spent much of the 1950s trying to describe mystical consciousness with enough precision that it could be studied rather than merely admired. Stace’s 1960 book, Mysticism and Philosophy, is where the framework this whole briefing rests on first took shape.
Stace noticed something that holds up remarkably well across traditions, cultures, and centuries: people describing a mystical experience tend to arrive at the same underlying claim, undifferentiated oneness, by one of two entirely different doors.
The first door closes the senses. Stace called this introvertive unity. You withdraw attention inward, away from the body, away from thought, away from the noise of the outer world, until what remains is not a thought about anything but a kind of pure, contentless awareness. No object. No observer separate from the observed. Just awareness itself, undifferentiated and complete. This is the unity described by a Zen practitioner sitting in deep meditation, or a contemplative monk deep in silent prayer.
The second door stays wide open. Stace called this extrovertive unity, and it is, if anything, the stranger of the two. Here the senses remain fully engaged. You still see the room, the trees outside the window, the faces of the people around you. Nothing about the ordinary furniture of the world disappears. What changes is what you sense underneath it: a living presence, a single “One,” running through everything and everyone you can see, so that nothing in the room is separate and nothing is merely dead matter. It is the experience captured in the old phrase “all is one,” except felt rather than reasoned toward.
I find it worth sitting with the fact that these are not two competing theories about what mysticism is. They are two different routes into what appears to be the same room. One arrives by subtraction, stripping away the senses until only awareness remains. The other arrives by addition, keeping every sense wide open until the boundaries between things simply stop holding. Both, Stace argued, count as genuine mystical unity. Clinical psychiatry, sixty years later, has quietly inherited this exact distinction, whether or not the researchers writing the papers have ever opened Stace’s book.
Nine Signs of the Same Territory
Stace gave psychiatry a philosophy of unity. What it still needed was a way to measure whether a person swallowing a capsule in a research lab was having that kind of experience, or something else entirely.
That work fell to Walter Pahnke, a Harvard doctoral student working under Timothy Leary in the early 1960s, whose 1963 dissertation, Drugs and Mysticism, built directly on Stace’s categories and refined them into something a researcher could score. Pahnke identified nine characteristics that, together, distinguish a classical mystical experience from an ordinary altered state, however intense. The first eight describe the acute experience itself, the peak moment. The ninth is different in kind: it asks not what happened in the room, but what changed afterward.
| Category | Description |
| Unity | A felt sense of oneness, whether introvertive or extrovertive. |
| Transcendence of Time and Space | Loss of the usual sense of temporal and spatial orientation. |
| Deeply Felt Positive Mood | Joy, love, or peace, felt with unusual intensity. |
| Sense of Sacredness | A felt sense of holiness or reverence, apart from any particular doctrine. |
| Noetic Quality | A conviction of having encountered ultimate or authoritative truth. |
| Paradoxicality | The comfortable acceptance of statements that are logically contradictory. |
| Ineffability | A sense that the experience exceeds what language can carry. |
| Transiency | The peak state’s inherently temporary nature. |
| Persisting Positive Changes | Longitudinal shifts in attitude toward oneself, one’s life, and other people. |
That last category is worth pausing on, because it is the one that turns a philosophical framework into a clinical one. A person can have an extraordinary hour and walk away unchanged by Tuesday. Pahnke’s ninth category asks whether the walls actually moved, whether a person’s relationship to their own life looks different months later. That is the question a therapist cares about, and it is the question this briefing keeps circling back to.
What Happened in the Chapel Basement
Pahnke did not stop at theory. For his dissertation, he designed what became known as the Marsh Chapel Experiment, and to history, more evocatively, as the Good Friday Experiment.
The design was rigorous for its time: a double-blind study, twenty Christian theology students from Andover Newton Theological School, randomly split into two groups of ten. One group received psilocybin. The other received niacin, chosen specifically because it produces a physical sensation, facial flushing and warmth, without touching the mind at all. Neither the participants nor, in principle, the observers knew who had received which capsule until the study was unblinded.
Almost every subject in the psilocybin group reported what could only be called a profound religious experience, scored against Pahnke’s nine categories at levels far exceeding the control group. Huston Smith, the religious studies scholar who was one of the participants, later described his experience that afternoon as “the most powerful cosmic homecoming I have ever experienced.” That is not the language of a mild mood change. That is the language of someone who felt, for an afternoon, that he had arrived somewhere he had always belonged.
It was not, however, uniformly gentle. One participant became convinced he had been chosen to announce the return of the Messiah, fled the chapel in acute distress, and required an injection of Thorazine, a powerful antipsychotic, to be safely restrained. That detail did not appear in Pahnke’s original published account of the experiment. It surfaced only later, and it matters for what comes next.
The Follow-Up No One Wanted to Publish
Roughly twenty-five years after that Good Friday, a young researcher named Rick Doblin, who would go on to found the Multidisciplinary Association for Psychedelic Studies, tracked down as many of the original participants as he could find and asked them, decades later, what that afternoon had actually meant to their lives. Interviewed in 1986 and published as a formal critique in 1991, Doblin’s follow-up found that all but one of the surviving psilocybin recipients still described the experience as containing genuine mystical elements and still ranked it among the high points of their entire spiritual lives. A quarter century had not dimmed it. If anything, it had settled into something closer to a permanent landmark in how these men understood their own lives.
But Doblin’s paper was not a celebration. It was, just as pointedly, a methodological reckoning. He documented that Pahnke’s original write-up had quietly omitted the acute anxiety several subjects experienced, including the Thorazine incident, and identified real problems with how the double-blind was implemented and how the outcome questionnaire had been worded. Here is the part I want you to sit with, because it is the more honest and more useful conclusion: Doblin did not use those flaws to throw out the experiment. He used them to sharpen the question. His conclusion was that the flaws cast no real doubt on the finding that drug-catalyzed mystical experiences are, in both their immediate content and their long-term effects, not inferior to mystical experiences that arise without any substance at all. A good result and a flawed method can be true at the same time. That is not a contradiction. That is what real research usually looks like on its way to getting better.
And it did get better. In 2006, more than four decades after the Marsh Chapel basement, researchers at Johns Hopkins, led by Roland Griffiths, ran a far more rigorous version of the same question with healthy, drug-naive adult volunteers under carefully supervised conditions. The results replicated what Pahnke had found: psilocybin, administered thoughtfully, reliably occasioned experiences that scored as genuinely mystical on the same categories Stace and Pahnke had described decades earlier. A follow-up published in 2008, fourteen months after the sessions, found that fifty eight percent of participants still rated their psilocybin experience among the five most personally meaningful events of their entire lives, alongside things like the birth of a child. Sixty-four percent reported that it had increased their life satisfaction and sense of well-being, and the effect had not faded with time.
Sixty years, three research teams, and one consistent finding: whatever this experience is, it does not evaporate. It lands, and it stays.
Meaning as Medicine
This is where the story stops being philosophy and history, and becomes something psychiatrists are now building treatment protocols around.
Modern researchers use a refined, thirty item version of Pahnke’s original scale, called the Mystical Experience Questionnaire, or MEQ-30, validated in a 2015 paper by Frederick Barrett, Matthew Johnson, and Roland Griffiths at Johns Hopkins. It lets a participant’s session be scored, quantitatively, against the same nine categories Pahnke identified in 1963. And what researchers have found, running that questionnaire against actual clinical outcomes, is the finding this entire briefing has been building toward.
In a 2017 study of patients with treatment-resistant depression, published in Frontiers in Pharmacology, researchers Leor Roseman, David Nutt, and Robin Carhart-Harris found that the intensity of “oceanic boundlessness,” a mystical-type quality of the acute experience, predicted symptom reduction at five weeks. Ordinary perceptual effects, the visual and sensory intensity most people associate with a psychedelic dose, carried almost no predictive weight at all. It was not how strange the experience looked. It was how unified it felt.
That finding has echoed across other trials since. In several studies now, MEQ-30 scores predict antidepressant response as well as, and in some cases better than, the physical dose of the drug itself. Sit with that for a moment, because it is a genuinely strange thing for a clinical trial to find. Two people can receive the identical milligram dose of psilocybin and walk away with very different outcomes, and the difference tracks not with their blood chemistry but with whether they encountered, in Pahnke’s language, a noetic quality: a felt conviction of having touched something true.
That noetic quality deserves its own moment of attention, because it is the hinge the whole convergence turns on. It is not merely feeling good. It is the conviction of having learned something, directly and without argument, about the nature of reality itself. Materialist psychiatry, working from a framework that has spent a century assuming the mind is what the brain does and nothing more, has now measured its way into a variable that contemplative traditions have described for millennia in almost identical language: unity, sacredness, a truth received rather than reasoned toward, and a change that persists. Two entirely different methods, one starting from double-blind trials and statistical significance, the other from silent monasteries and centuries of contemplative practice, have been independently triangulating on the same territory.
What This Actually Means
I do not think it is an accident that the compound now furthest along in FDA review, psilocybin, is also the one most reliably associated with this kind of experience, or that the trials measuring it best are the ones showing the clearest signal. Clinical psychiatry did not set out looking for mysticism. It set out looking for what predicts recovery, followed the data honestly, and arrived, from a completely different direction, at a variable the contemplative traditions have been describing since long before anyone thought to call it a variable.
That convergence is worth taking seriously on its own terms, without overselling it into something it is not. A profound mystical experience is not a guarantee of healing, and not every person who benefits from psilocybin-assisted therapy describes anything close to Huston Smith’s cosmic homecoming. But when researchers ask, carefully and quantitatively, what best predicts who gets better, the answer keeps coming back not to the chemistry alone, but to whether a person, for however brief a window, touched something they experienced as real, sacred, and unified. Sixty-four years after that Good Friday in a chapel basement, medicine is still catching up to what those twenty divinity students already knew before the study was even unblinded.
Selected Sources
Stace, W.T. Mysticism and Philosophy. Macmillan, 1960.
Pahnke, W.N. “Drugs and Mysticism: An Analysis of the Relationship Between Psychedelic Drugs and the Mystical Consciousness.” Doctoral dissertation, Harvard University, 1963.
Doblin, R. “Pahnke’s ‘Good Friday Experiment’: A Long-Term Follow-Up and Methodological Critique.” Journal of Transpersonal Psychology, 23(1), 1991.
Griffiths, R.R., Richards, W.A., McCann, U., and Jesse, R. “Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance.” Psychopharmacology, 187(3), 2006.
Griffiths, R.R., Richards, W.A., Johnson, M.W., McCann, U.D., and Jesse, R. “Mystical-Type Experiences Occasioned by Psilocybin Mediate the Attribution of Personal Meaning and Spiritual Significance 14 Months Later.” Journal of Psychopharmacology, 22(6), 2008.
Barrett, F.S., Johnson, M.W., and Griffiths, R.R. “Validation of the Revised Mystical Experience Questionnaire in Experimental Sessions with Psilocybin.” Journal of Psychopharmacology, 29(11), 2015.
Roseman, L., Nutt, D.J., and Carhart-Harris, R.L. “Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression.” Frontiers in Pharmacology, 8, 2017.
Wikipedia contributors. “Marsh Chapel Experiment.” Wikipedia, The Free Encyclopedia, accessed August 2026.
Johns Hopkins Center for Psychedelic and Consciousness Research. “History.” hopkinspsychedelic.org, accessed August 2026.